Patents by Inventor Hermann Kulmann

Hermann Kulmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8536156
    Abstract: A method for hormonal contraception comprising administering at least one contraceptive hormone in a plurality of linked taking periods optionally having a sequence lasting several years. Each taking period comprises at least one taking cycle. Each taking cycle comprises a duration-constant taking phase lasting several days and a taking pause lasting several days. In each taking phase the hormonal component is administrated in a daily unit. In each taking pause either a placebo or no unit is administered. The duration of the taking phase or phases of at least the final taking period is at least 22 days. The duration of each taking phase in any taking period preceding a following taking period is shorter than that in each of the taking phases in each following taking period.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: September 17, 2013
    Assignee: Bayer Intellectual Property GmbH
    Inventor: Hermann Kulmann
  • Publication number: 20120129823
    Abstract: A method for hormonal contraception comprising administering at least one contraceptive hormone in a plurality of linked taking periods optionally having a sequence lasting several years. Each taking period comprises at least one taking cycle. Each taking cycle comprises a duration-constant taking phase lasting several days and a taking pause lasting several days. In each taking phase the hormonal component is administrated in a daily unit. In each taking pause either a placebo or no unit is administered. The duration of the taking phase or phases of at least the final taking period is at least 22 days. The duration of each taking phase in any taking period preceding a following taking period is shorter than that in each of the taking phases in each following taking period.
    Type: Application
    Filed: December 12, 2011
    Publication date: May 24, 2012
    Inventor: Hermann KULMANN
  • Patent number: 8076317
    Abstract: Process for hormonal contraception, in which in a plurality of substantially time-unlimited, linked taking periods and optionally having a sequence lasting several years and which in each case comprise at least one taking cycle with a duration-constant taking phase lasting several days within the particular taking period and a taking pause lasting several days, in which taking phase or phases per day administration takes place of a daily unit with at least one contraceptively acting hormone component, such as estrogen and/or gestagen, and in the taking pause or pauses administration takes place either of placebos free from any hormone component or the particular taking pause remains entirely administration-free and the duration of the taking phase or phases of at least the final taking period last at least 22 days, characterized in that the duration of the taking phase or phases in any taking period proceeding a following taking period is shorter than in each case following taking period, as well as administr
    Type: Grant
    Filed: September 5, 2001
    Date of Patent: December 13, 2011
    Assignee: Bayer Pharma AG
    Inventor: Hermann Kulmann
  • Patent number: 7871994
    Abstract: Method for hormone replacement therapy, in which at least in the established postmenopause a daily unit with at least one hormonal component, namely with at least estrogen (E) and/or at least one gestagen (G) is administered permanently and continuously every day, characterized in that in at least one ingestion period preceding the permanent administration of hormone daily units is provided an ingestion pause (P), in which either no daily units or placebos or daily units with a much lower estrogen and/or gestagen content than during the permanent administration of hormone daily units in the established postmenopause and during the ingestion phase(s) of the preceding ingestion period are administered, as well as administration form for hormone therapy.
    Type: Grant
    Filed: January 8, 2002
    Date of Patent: January 18, 2011
    Assignee: Bayer Schering Pharma AG
    Inventor: Hermann Kulmann
  • Publication number: 20040219174
    Abstract: Process for hormonal contraception, in which in a plurality of substantially time-unlimited, linked taking periods and optionally having a sequence lasting several years and which in each case comprise at least one taking cycle with a duration-constant taking phase lasting several days within the particular taking period and a taking pause lasting several days, in which taking phase or phases per day administration takes place of a daily unit with at least one contraceptively acting hormone component, such as estrogen and/or gestagen, and in the taking pause or pauses administration takes place either of placebos free from any hormone component or the particular taking pause remains entirely administration-free and the duration of the taking phase or phases of at least the final taking period last at least 22 days, characterized in that the duration of the taking phase or phases in any taking period proceding a following taking period is shorter than in each case following taking period, as well as administra
    Type: Application
    Filed: September 29, 2003
    Publication date: November 4, 2004
    Inventor: Hermann Kulmann
  • Publication number: 20040106586
    Abstract: Method for hormone replacement therapy, in which at least in the established postmenopause a daily unit with at least one hormonal component, namely with at least estrogen (E) and/or at least one gestagen (G) is administered permanently and continuously every day, characterized in that in at least one ingestion period preceding the permanent administration of hormone daily units is provided an ingestion pause (P), in which either no daily units or placebos or daily units with a much lower estrogen and/or gestagen content than during the permanent administration of hormone daily units in the established postmenopause and during the ingestion phase(s) of the preceding, ingestion period are administered, as well as administration form for hormone therapy.
    Type: Application
    Filed: January 14, 2004
    Publication date: June 3, 2004
    Inventor: Hermann Kulmann